Sankyo Ceases Clinical Studies of Pactimibe, Investigational Drug for ASCVD.Tokyo, Japan, Oct 28, 2005 - (JCNN) - Daiichi Sankyo announced on October 26 that its subsidiary Sankyo has decided to cease its ongoing clinical studies of pactimibe (CS-505), an investigational drug for the treatment of arteriosclerotic ar·te·ri·o·scle·ro·sis n. A chronic disease in which thickening, hardening, and loss of elasticity of the arterial walls result in impaired blood circulation. It develops with aging, and in hypertension, diabetes, hyperlipidemia, and other conditions. cardiovascular disease (ASCVD ASCVD arteriosclerotic cardiovascular disease. ASCVD abbr. arteriosclerotic cardiovascular disease ASCVD Arteriosclerotic cardiovascular disease. ). The agent pactimibe is an acyl-coenzyme A: cholesterol acyltransferase (ACAT ACAT See: Automated Customer Account Transfer ) inhibitor. The decision was made because the company could not obtain favorable results from the current phase II clinical study named the ACAT Intravascular intravascular /in·tra·vas·cu·lar/ (in?trah-vas´ku-lar) within a vessel. in·tra·vas·cu·lar adj. Within one or more blood vessels. Atherosclerosis Treatment Evaluation (ACTIVATE) study conducted in the US. Detailed results of the ACTIVATE study will be presented at the 2005 American Heart Association's Scientific Sessions to be held in Texas on November 15. Source: JCN http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion